儿童系统性红斑狼疮的诊断与治疗  

Diagnosis and treatment strategy of childhood-onset systemic lupus erythematosus

作　　者：周纬[1] ZHOU Wei(National Children's Medical Center,Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China)

机构地区：[1]国家儿童医学中心上海交通大学医学院附属上海儿童医学中心,上海200127

出　　处：《临床儿科杂志》2022年第10期721-725,共5页Journal of Clinical Pediatrics

摘　　要：儿童系统性红斑狼疮(cSLE)是一种自身免疫性疾病,以全身多脏器受累、体内有大量自身抗体和低补体血症为主要临床特点,受累脏器易不可逆损伤而危及生命。文章介绍了cSLE临床特征、重症狼疮和单基因SLE,总结了cSLE诊断方法、病情评估、达标治疗、治疗原则和不同受累脏器的治疗方案,提出了传统治疗与生物制剂联合的治疗策略,以更好地针对cSLE发病机制、尽早充分治疗、尽快控制疾病活动、减少疾病复发和传统药物的不良反应,为cSLE诊断和治疗的不断完善提供参考。Childhood-onset systemic lupus erythematosus(cSLE)is an autoimmune disease characterized by multiple organ involvement,a large number of autoantibodies and low complement.The affected organs are prone to irreversible damage,which threatens the lives of children.This article introduces the clinical characteristics of cSLE,severe lupus and monogenic lupus,and summarizes the diagnosis methods,disease activity assessment,treat-to-target,treatment principles and treatment schemes for different organ involvement of cSLE,and puts forward the treatment strategy of combination of traditional treatment and biological drugs,so as to better target the pathogenesis of cSLE,fully treat and control disease activity as soon as possible,reduce disease recurrence and side effects of traditional drugs,and provide reference for the continuous improvement of diagnosis and treatment of cSLE.

关 键 词：系统性红斑狼疮 单基因 生物制剂 达标治疗 儿童 

分 类 号：R725.9[医药卫生—儿科]